In the past decade, adenovirus vectors have generated tremendous interest, especially in gene therapy applications. In the so-called 'first generation' adenovirus vectors, the transgenes are inserted in place of the E1 region, or less often the E3 region. Although second-generation and helperdependent adenovirus vectors will probably prevail in the future in applications that require long-term gene expression, first generation adenovirus vectors will remain very useful in
Introduction
Adenovirus vectors have become a very popular tool for gene transfer into mammalian cells. [1] [2] [3] [4] [5] [6] [7] They have numerous advantages: they can infect a wide variety of dividing or nondividing cells; they are easily purified to high titers; the strains commonly used to construct recombinant viruses (Ad2, Ad5) are well characterized; they can accommodate up to 37 kb foreign genetic material; 8 their genome rarely integrates into the host chromosome, which is suitable for applications requiring transient gene expression; 9 and hybrid adenovirus/retrovirus or adenovirus/adeno-associated virus vectors can be used to achieve integration of transgenes into the genome and long-term gene expression. 10, 11 Over the years, many methods for manipulating the viral genome have been developed. We will review the approaches that are used to produce standard, so-called first generation adenovirus vectors.
Three classes of adenovirus vectors are currently being developed for gene therapy purposes ( Figure 1 ). First generation adenovirus vectors are made by substituting an expression cassette for the E1 and/or E3 regions. The E1 region, located at the left end of the 36 kb adenovirus genome, encodes proteins necessary for the expression of the other early and late genes. Various deletions of this region have been made, with a maximum of 3150 bp. Since the E1 products are necessary for viral growth, they must be provided in trans in specific cell lines, such as 293, 12 911, 13 or PER.C6. 14 The E3 region encodes products that counteract host defense mechanisms; these products are not essential for viral replication in vitro, and therefore no complementing cell line is necessary. 15 However, in some applications, it might be desirable to retain or even increase the expression of some E3 products: for instance, the adenovirus 'death protein' E3-11.6K, which facilitates the release of viral particles from infected cells, 16 or gp19K, whose constitutive expression reduces the host cytotoxic T cell response against the vector 17 and increases the persistence of transgene expression on its own, 18 [26] [27] [28] or all or most of the E4 products. [29] [30] [31] [32] [33] [34] [35] The corresponding deletions on the viral genome should allow the insertion of expression cassettes up to 14 kb. A third class of adenovirus vectors is represented by the so-called 'gutted' or 'helper-dependent' adenoviruses. [36] [37] [38] [39] [40] [41] These vectors are deleted for all viral genes, but retain the cis-acting sequences necessary for viral DNA replication and packaging. Such viruses can in theory accommodate multiple transgenes, totaling about 37 kb. However their production is tedious and needs to be optimized.
First generation adenovirus vectors remain an invaluable tool for gene transfer. Their transgene capacity is compatible with most applications and they are easy to grow to high titers. They can be used not only in gene therapy, particularly in settings in which the immune response is not an issue such as cancer, but also to express recombinant proteins for vaccination purposes, or simply to transduce cell lines that are refractory to other transfection methods. Until a few years ago, the construction of adenovirus vectors was a time-consuming process, requiring 2 to 3 months of intensive labor. The past few years have seen the proliferation of techniques which facilitate the construction of first generation vectors, and which are reviewed below.
Methods requiring DNA recombination in mammalian cells
The classical method to generate E1-substituted adenovirus vectors requires recombination between two DNA molecules, one carrying sequences mapping to the very left end of the adenovirus genome and the gene of interest, and the other carrying sequences that slightly overlap the 3Ј-most viral sequences on the first molecule and continue to the right end of the adenovirus genome. The latter, which we will refer to as right end sequences for simplicity, can be either a linear DNA purified from virions, or a plasmid. This recombination takes place inside E1-expressing cells such as 293 cells, generating the desired recombinant viral DNA.
Originally, the right end of the adenovirus genome was obtained by digesting viral DNA with a restriction enzyme(s) that cuts in the E1 region (Figure 2a) . 42 Because of the small difference in size between the undigested and digested viral DNAs, it is difficult to verify the completeness of the digest by agarose gel electrophoresis or to separate the two DNAs for purification. This can be a problem because undigested viral DNA will generate virus more efficiently than the recombination product, leading to the contamination of the recombinant virus preparation with the parental virus. Moreover, the small restriction fragments that correspond to the left end of the genome and are carried over during the transfection can religate inside the cell and generate replication-competent adenovirus. 43, 44 Therefore two or three rounds of purification by plaque assay must be performed, and multiple plaques must be analyzed to identify the recombinant virus. A second disadvantage of this method is that the recombination event, which is required to link the left adenovirus sequences carrying the gene of interest to the right end sequences, is inefficient in mammalian cells. Therefore it usually takes up to 2 weeks for the recombinant virus to appear.
Three methods have been developed to facilitate the detection and purification of the recombinant virus. By using a viral DNA in which the E1 region is replaced by a cassette expressing the HSV thymidine kinase (tk) gene, 45 counter-selection against the parental background virus can be performed by adding ganciclovir to the agar overlay. This counter-selection is reliable only on a secondary plaque assay, however, as the primary plaques obtained directly after transfection may originate from cells that have taken up multiple viral genomes and contain both the tk-expressing parental virus and the recombinant virus. Similarly, viral DNA in which the E1 region is replaced by a cassette expressing E. coli ␤-galactosidase 43 or a green fluorescent protein 46 can be used as parental DNA. Plaques containing background virus are detected either by staining with X-gal, or by fluorescence microscopy, respectively. These two methods reportedly allow the isolation of the recombinant virus during the first round of purification. It would be more cautious however, and proper virological procedure, to perform a second round of plaque purification, as suggested for the tk-expressing virus.
The adenovirus DNA-terminal protein complex can generate viral plaques with an efficiency two to three orders of magnitude higher than naked DNA prepared with proteinase. For decades, such complexes have been used to construct recombinant adenoviruses. [47] [48] [49] [50] More recently, a technique has been adapted in which the DNA-terminal protein complex is digested with a restriction enzyme at several sites in the Ad5 genome, better preventing the regeneration of the parental virus. 51 The expression cassette is cloned into a cosmid containing a full-length copy of the adenovirus genome. Both the circular cosmid and the digested viral DNA are transfected into helper cells. A few hundred plaques, which arise by recombination of the full-length cosmid-derived genome with the two terminal protein-linked genome ends, are usually obtained using this procedure, among which about 70% are positive for the presence of the expression cassette.
To overcome the inefficiency of homologous recombination in mammalian cells, a technique has been developed that uses the bacteriophage P1 Cre-lox recombination system. 52 This system is composed of three elements: (1) a recombinant adenovirus that contains two loxP sites flanking the packaging signal; (2) a shuttle vector which contains the left ITR, the packaging signal, the expression cassette and a loxP site; (3) a 293-derived cell line which expresses the phage P1 Cre recombinase. To generate E1-substituted adenovirus vectors, the shuttle vector carrying the gene of interest and the viral DNA are co-transfected into the helper cells. First, an intramolecular recombination occurs between the two loxP sites present in the viral DNA. This generates an adenovirus genome which is able to replicate and express viral genes, but is unable to be packaged. A second recombination occurs between the loxP site of this product and that on the shuttle vector, generating the desired recombinant virus. The main disadvantage of this method is the persistence of the parental virus in the preparation, which can represent up to 30% of the viral population after the first passage, and still constitutes 0.2% after three passages. Therefore, this method requires a careful verification of the identity of the recombinant virus.
A very recent improvement of this technique was obtained by using adenovirus DNA isolated from plasmids instead of viral particles. 53 A large plasmid was constructed that contains the Ad5 backbone devoid of the left ITR, the packaging signal, and the E1 sequences. This plasmid, linearized at a site flanking the right ITR, is cotransfected into helper cells with a shuttle plasmid that contains the left adenovirus sequences and the expression cassette. Virus is generated upon homologous DNA recombination between both DNA molecules. Unlike the above-described methods, contamination with parental Gene Therapy virus is not possible, and therefore a limited number of plaques needs to be analyzed.
Another approach to construct recombinant adenovirus vectors relies on the ability of circular adenovirus DNAs to generate virus upon transfection into 293 cells (Figure 2b) . 20, 54 These circular viral DNAs contain an ampicillin resistance gene and a bacterial origin of replication in place of the E1 region, and are therefore able to replicate in E. coli as plasmids. These vectors have been subsequently modified to increase their size to about 40 kb, or have been deleted for their packaging signal. These features render the parental molecules unable to be packaged into virions, and therefore a homogeneous recombinant virus preparation should be obtainable. In this system, the gene of interest is cloned into a small plasmid containing the left end of the adenovirus genome. The resulting plasmid, linearized, is co-transfected into helper cells with the circular adenovirus plasmid. Recombination must occur between both DNAs to create a molecule that can be replicated and packaged to generate the recombinant virus. The same technique can be used to insert expression cassettes in the E3 region, or in both the Gene Therapy E1 and E3 regions. However, manipulation of these large plasmids in E. coli is rendered difficult because of the presence of a 200-bp long palindromic sequence that results from the juxtaposition of the left and right adenovirus ITRs in the plasmid construct. Such structures are known to be unstable in E. coli and deleterious for bacterial growth. 55 Moreover, the formation of plaques upon transfection of circular adenovirus DNA has been reported to be inefficient, 41 probably because imbedded adenovirus ITRs initiate DNA synthesis less efficiently than those at the ends of linear DNA. 56 A 293 cell line constitutively expressing the adenovirus preterminal protein and DNA polymerase can be used to overcome this replication problem. 41 As for the techniques using linear viral DNAs, this homologous recombination method was improved using the Cre-lox recombination system. In a first embodiment, loxP sites were inserted in both the large circular adenovirus DNA and the small shuttle plasmid. 57 Recombinant adenovirus is obtained as a result of Cre-mediated recombination between both plasmids after their cotransfection into a 293 cell line expressing Cre recombinase. The frequency of virus rescue using this specific recombination system is significantly higher (approximately 30-fold) than by in vivo homologous recombination. In a second embodiment, the E1 region of the circular form of adenovirus DNA is replaced with a cosmid vector flanked by loxP sites. 58 As above, this replacement produces a DNA molecule too large to be packaged into virions. Expression cassettes are inserted between the loxP-flanked cosmid backbone and the adenovirus genome via packaging into phage . The resulting cosmid is transfected into helper cells that express the Cre recombinase. An intramolecular Cre-lox mediated recombination excises the cosmid vector backbone and produces a molecule that can be packaged into virions. Using this method, viral plaques are observed between 8 and 10 days after transfection.
Methods reconstructing the recombinant adenovirus genome before transfection into mammalian cells
A second category of methods is based on the construction of the recombinant adenovirus genome before transfection into helper cells. All these methods but one 59 have the advantage that the transfections are performed using DNAs isolated from bacterial clones, and generate virus preparations devoid of parental virus. The only potential concern is the absence of selective pressure for the adenovirus sequences in E. coli, which could lead to mutations that impair the viability of the virus.
In vitro DNA ligation was already in use two decades ago to construct recombinant adenoviruses. 59 A large DNA fragment obtained by digesting virion DNA in the E1 region is ligated with a plasmid DNA fragment containing the adenovirus left ITR, the packaging signal, and the expression cassette. Transfection of the ligation products into helper cells results in the production of the recombinant virus. However, this technique is prone to contamination of the virus progeny by the parental virus and therefore careful virus purification by plaque assay is essential.
More recently, a method was designed to construct the recombinant viral DNA in vitro using the Cre-lox recombination system (Figure 3a) . 60 The expression cassette is cloned into a small intermediate vector that contains the left ITR, packaging signal, a multiple cloning site, and a loxP site. The resulting plasmid is linearized at a site flanking the left ITR, and incubated with Cre recombinase and a linearized cosmid DNA which contains another loxP site in place of the E1 region. Since the cosmid DNA lacks the left ITR and packaging signal, only the recombination products are able to generate virus after transfection in helper cells. Recombinant virus can be effectively obtained 7-9 days after transfection.
Three methods have been published that describe the generation of recombinant adenovirus by recombination in E. coli. 30, 61, 62 All three methods involve two elements, a large plasmid containing the entire adenovirus genome (or just the right end), and a small shuttle plasmid containing the expression cassette flanked by sequences homologous to the region to be targeted. In the technique developed by Chartier et al, 61 the large adenovirus plasmid is linearized at a unique site located in the E1 region or near the E3 region. This DNA is introduced into a RecA + E. coli strain together with a DNA fragment containing the gene of interest flanked by E1 or E3 sequences. Recombination between both DNA molecules generates a plasmid containing the expression cassette in the desired region, with an efficiency ranging from 20 to 100%. Background colonies arise when the adenovirus plasmid is not completely linearized or when the purified fragment is contaminated with the vector backbone carrying an ampicillin-resistance gene. Transformants are screened for the presence of the gene of interest and the recombinant plasmid is transferred to a standard RecA − E. coli strain in order to isolate larger quantities of plasmid DNA. The plasmid is finally digested to release a linear adenovirus DNA, and transfected into helper cells. This method is very powerful for introducing expression cassettes in the E1 or E3 region, or mutations in any region of the genome as long as a unique restriction site is present in that region. 63 A very similar method was designed to introduce expression cassettes specifically into the E1 region, and facilitate the recovery of the recombinant E. coli clones. 30 The large adenovirus plasmid is introduced into E. coli as a supercoiled DNA in order to increase transformation efficiency, and a kanamycin-resistance gene, provided by the shuttle vector containing the expression cassette, is used to select the recombinant clones. With this technique, about 60% of the kanamycin-resistant colonies contain the desired recombinant plasmid. As above, recombinant plasmid DNA is purified, and the viral chromosome is released by restriction digestion and transfected into the appropriate cell line.
The third recombination method in E. coli involves a two-step gene replacement protocol. 62 A co-integrate plasmid is first obtained by recombination between a large adenovirus plasmid and a small shuttle vector that contains the gene of interest, and selected for in the presence of two antibiotics. The final recombinant plasmid is generated via a second homologous recombination event that excises from the co-integrate B. subtilis sacB sequences, which encodes a protein that kills the bacterium in the presence of sucrose. The technique generates a 50-50 mixture of parental and recombinant plasmids. It therefore requires a thorough verification of the recombinant adenovirus plasmid by restriction or Southern analysis before isolation of the viral genome and transfection into cells. Compared to the two methods described above, this technique does not require the linearization of either the adenovirus or the shuttle plasmid before transformation. Moreover, this method has the advantage of allowing insertion of mutations or heterologous sequences at any location in the adenovirus genome.
A few techniques have been designed to insert expression cassettes in adenovirus plasmids by ligation rather than recombination. These procedures are more straightforward since only one E. coli strain is used for both plasmid construction and amplification, and there is less danger of unpredicted recombination events that might go undetected and generate noninfectious viral DNA. Two similar methods use large plasmids which contain the entire sequence of the adenovirus genome, with one or two unique recognition sites for intron-encoded endonucleases in place of the E1 region. [64] [65] [66] The expression cassettes are cloned into small shuttle vectors that contain these specific sites, and are subsequently transferred into the large adenovirus plasmids. In the first method, 64 construction of the recombinant plasmid
Gene Therapy is achieved with an efficiency approaching 50%. In the second method, 65,66 a counter-selection against the parental adenovirus plasmid is performed by digesting the ligation reaction with a third enzyme. This raises the cloning efficiency to 90%. The recombinant adenovirus plasmid is amplified, digested to expose the inverted terminal repeats and then transfected into helper cells to rescue the virus. Viral plaques are visible after 7 to 10 days.
Since transformation of E. coli with large plasmids generates a background of smaller plasmids due to rearrangements, other techniques have been designed that reconstitute the sequence of the recombinant virus in a cosmid. This technology is particularly well suited for the cloning of the 36-kb long adenovirus genome, since phage lambda preferentially packages DNAs ranging from 38 to 51 kb. 67 In a first approach, the cosmid containing the sequence of the recombinant virus is directly transfected into helper cells, apparently without linearization of the DNA before transfection. 68 This method is inefficient in generating plaques, probably because of the inefficiency of replicating viral genomes whose ends are imbedded. 56 To overcome this problem, another cosmid vector was developed, from which the recombinant adenovirus genome can be released by Gene Therapy restriction digestion before transfection into helper cells. 69 This cosmid vector contains unique cloning sites in the E1 and E3 regions, allowing the insertion of two transgenes into the adenovirus genome.
In another approach, an adenovirus cosmid is constructed using three vectors containing the left end, the middle region and the right end of the adenovirus genome. 70 One or two expression cassettes are inserted into the E1 or the E3 region, using the left or the right end vector, respectively. By choosing a set of three or four restriction enzymes that are present naturally in the adenoviral genome and allow for directional cloning, large DNA fragments are generated, and ligated to reconstruct a cosmid containing the sequence of the recombinant virus. After purification, the cosmid DNA is digested to release the viral genome and transfected into a packaging cell line. Virus is recovered on average 7 days later. This method has the advantage of allowing the introduction of two independent expression cassettes at different places in the genome in two cloning steps. However, the choice of restriction enzymes suitable for directional cloning is limited given the size of the genome, and the purification of large DNA fragments on agarose gels is difficult. To circumvent these problems, two improved methods have been designed that facilitate the construction of a cosmid containing one or two expression cassettes in the E1 and/or the E3 region (Figure 3b) . 71, 72 The expression units are cloned into small bacterial vectors, and thereby linked to positive selection bacterial markers. Using versatile sets of restriction enzymes that flank these sequences and allow for directional cloning, the expression units and the positive selection markers are transferred to large plasmids containing the adenovirus sequences, with an efficiency approaching 100%. The cosmid DNA is purified, linearized and transfected into helper cells. As for the other plasmid-based methods, viral plaques appear on average 7 days, and sometimes as early as 4 days, after transfection.
Finally, a method to reconstruct the sequence of the recombinant adenovirus DNA in yeast before transfection into helper cells has also been reported. 73 These investigators used a yeast artificial chromosome which contains the full-length sequence of adenovirus DNA, and inserted the gene of interest using a double-step gene replacement procedure. Unfortunately, this technique has proven difficult to reproduce.
Which method to use?
Time and labor are the major factors that come into consideration when choosing a method to construct adenovirus vectors, and ideally they should be minimized. The individual investigator's comfort with the various experimental procedures is also of obvious importance. All the techniques described above include one or several cloning steps in E. coli, transfection into a packaging cell line, and the purification of one or several candidate recombinant viruses by plaque assay. The most time-consuming step is certainly the last one. Is this step necessary for all methods, and if yes, how many plaque assays are needed?
Contamination of a recombinant viral preparation can originate from three sources: the parental virus, replication competent adenoviruses (RCA), and mutant viruses. Since the parental virus is generally the major source of contamination, methods that use exclusively plasmid DNA for the transfections will maximize the chance of obtaining the right clone and minimize labor since fewer plaques will have to be analyzed. Methods that reconstitute the sequence of the recombinant adenovirus before transfection into helper cells also avoid the homologous recombination step in helper cells, which is clearly another rate-limiting step for virus generation. All these techniques but two 53, 60 require one or two additional cloning steps in E. coli, but in compensation, allow one to transfect helper cells with larger amounts of DNA and to recover viral plaques more rapidly. A potential problem of these methods is the instability of the large adenovirus plasmids in E. coli. This is particularly the case for plasmids that contain large palindromes comprising the ITRs. 20, 58 Reconstituting the sequence of the virus by recombination in E. coli is slightly less straightforward than using conventional ligation approaches, because at least one more step is needed to amplify the adenovirus plasmid. These recombination-based methods also present the danger of unpredicted recombination events that might go undetected and generate noninfectious adenovirus plasmids. It is generally a good idea, therefore, to use more than one independent clone for transfection. The advantage of some of these techniques, 61, 62 however, is that they are helpful for introducing mutations at any place in the adenovirus genome. Finally, construction of adenovirus plasmids by ligation in E. coli is greatly facilitated by using cosmid technology since almost 100% of the bacterial clones are positive. [70] [71] [72] Replication-competent adenoviruses are generated by recombination between the recombinant viral DNA and the adenovirus sequences integrated into the genome of the helper cells. The occurrence of RCA is very low in the first passages of the virus 74 and can be avoided if cell lines such as PER.C6, 14 which do not contain sequences overlapping the viral chromosome, and appropriate vectors are used. Contamination by variants derived from the recombinant virus is a problem that can affect all methods. Since the viral DNA polymerase does not have the same degree of proofreading activity as its cellular counterpart, 75 the mutation rate of viral DNA is much higher than that of cellular DNA. A mutant virus could have a growth advantage over the desired recombinant virus if, for instance, the latter expresses a gene that interferes with the viral replication cycle, and mutations in viral genes on the recombinant chromosome might interfere with growth of the recombinant itself. A priori it is difficult to predict whether an expression cassette, or a specific DNA sequence inserted into the genome, will be detrimental to virus growth. One should therefore be cautious in drawing conclusions from experiments using crude adenovirus extracts obtained directly from transfected cells, even if those were transfected with a plasmid isolated from a single E. coli clone. Ideally, two rounds of plaque assays should be performed and all stocks should be checked for the presence of RCA, particularly when in vivo studies are being performed.
The future of first generation adenovirus vectors
Several straightforward methods are now available to construct first-generation recombinant adenoviruses. Each investigator should choose a method, taking into account the advantages and disadvantages of each, along with his or her own experimental strengths. However, it should be kept in mind that a recombinant virus might prove unstable and therefore plaque assays should always be performed, regardless of the method used. Although first generation adenovirus vectors might be supplanted in the future by gutted vectors, especially in replacement gene therapy settings that require long-term gene expression, they will remain an invaluable alternative for applications in which the immune response can be tolerated or might even be desirable, such as cancer or vaccination, for recombinant protein expression, or to transfer genes into cell lines that are refractory to other transfection methods.
